You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.
The assay detects 10 STIs and is performed on the molecular point-of-care Vivalytic platform, which was codeveloped by German company Bosch.
All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.
The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.
Stakeholders discussed last year's decision by Palmetto to deny coverage for large respiratory panels and discussed the way forward for test developers and labs.
The company reported total revenues of $27.7 million, with growth in its consumables business but a drop in instrument revenues from the prior year's first quarter.
The Maxpar Direct Immune Profiling System could lower the threshold to doing mass cytometry due to ease of use, a core lab director said.
A NorthShore University HealthSystem and Color pilot picked up pathogenic variants in nearly 9 percent of unselected individuals with a hereditary cancer gene test.
The company signed distribution agreements covering 15 countries for its PlexWell technology and products for multiplexed NGS applications.
The firm's suite of tests, based on its Factorial system, produce cellular signatures offering clues to a compound's toxicity and the types of pathways it perturbs.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.